Clinical Trial Update: Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor [Phase 3]

View source ↗

Summary

Phase 3 trial comparing palbociclib plus cetuximab versus cetuximab alone in CDKN2A-altered, HPV-unrelated head and neck squamous cell carcinoma that progressed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hpv-unrelated Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Cetuximab (cetuximab)
• Palbociclib (palbociclib)

Snippet

Sponsor: Washington University School of Medicine | Conditions: HPV-unrelated Head and Neck Squamous Cell Carcinoma | Phase 3 | Status: RECRUITING